Option chain shows key data for Eisai Co's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Eisai Co.

Eisai Co (OTC:ESAIY) Stock, Option Chain

Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of a pharmaceutical business and other businesses. The pharmaceutical business is categorized by region, including Japan, Americas, China, Asia, and Europe, Middle East, and Africa. Eisai also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived by its Japanese pharmaceutical business, followed by its Americas pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.

Test,Tube,Row.,Concept,Of,Medical,Or,Science,Laboratory,,Liquid

Biotech

Large Cap

News

Health Care

General

ESAIY

ESALF

Merck and Eisai report mixed results from LEAP-015 trial of Keytruda and Lenvima in HER2-negative gastroesophageal cancer treatment.

Merck/Eisai&#39;s Keytruda Plus Lenvima Regime Shows Mixed Data In Esophagus Cancer Study

Brain,Degenerative,Diseases,Parkinson,,Alzheimer,,Puzzle

BIIB

The U.K.&#39;s Medicines and Healthcare products Regulatory Agency approved Eisai and Biogen&#39;s Leqembi for treating mild cognitive impairment and mild dementia due to Alzheimer&#39;s. Despite this, NICE stated the drug&#39;s benefits are too small to justify the cost for NHS use.

Biogen&#39;s Alzheimer&#39;s Drug Secures UK Approval, But An Independent Agency Does Not Recommend Reimbursement

Analyst Color

Reiteration

Analyst Ratings

Movers

Trading Ideas

The FDA has approved Eli Lilly&#39;s Kisunla (donanemab) for early symptomatic Alzheimer&#39;s disease. Kisunla, targeting amyloid plaques, shows a significant reduction in disease progression and may reduce treatment costs with fewer infusions. Priced at $32,000 annually, it offers a competitive option against Biogen&#39;s Leqembi.

Eli Lilly&#39;s Alzheimer&#39;s Therapy&#39;s Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst

Eisai Co Ltd

Eisai Co

Comments

Eisai Co

Eisai Co (ESAIY) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga